Rigel Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Sponsored Research and License Agreements (Details)

Sponsored Research and License Agreements (Details) - USD ($)	1 Months Ended			3 Months Ended					9 Months Ended		34 Months Ended
	Jan. 31, 2024	Dec. 31, 2023	Apr. 30, 2021	Sep. 30, 2026	Jun. 30, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Dec. 31, 2025
Collaborations
Upfront payment received			$ 125,000,000.0
Revenue recognized				$ 80,890,000		$ 69,462,000			$ 218,411,000	$ 224,480,000
ocadusertib
Collaborations
Company's percentage of development costs									20.00%
Revenue recognized							$ 40,000,000.0
Grifols
Collaborations
Deferred revenue				0					$ 0		$ 0	$ 0
Grifols \| Royalty
Collaborations
Revenue recognized				2,500,000		1,900,000			6,200,000	5,000,000.0
Kissei
Collaborations
Deferred revenue				0					0		0	0
Revenue recognized				3,200,000		1,800,000			6,700,000	3,900,000
Kissei \| fostamatinib
Collaborations
Deferred revenue				1,400,000					1,400,000		1,400,000	1,400,000
Revenue recognized					$ 4,200,000			$ 3,000,000.0
Sublicensing fee payable					$ 1,000,000.0
Medison \| fostamatinib
Collaborations
Deferred revenue				0					0		0	$ 0
Revenue recognized				300,000		200,000			900,000	800,000
Non-Central Nervous System, Specified Development And Regulatory Milestone
Collaborations
Contingent payments									330,000,000.0
Product-by-product Sales Milestone
Collaborations
Contingent payments									100,000,000.0
Central Nervous System, Specified Development And Regulatory Milestone
Collaborations
Contingent payments									256,000,000.0
Central Nervous System, Product-by-product Sales Milestone
Collaborations
Contingent payments									150,000,000.0
Delivery of drug supply for commercialization \| Grifols
Collaborations
Revenue recognized				$ 1,200,000		$ 1,200,000			4,300,000	$ 4,900,000
Collaborative Arrangement
Collaborations
Contingent payments									652,100,000
Collaborative Arrangement \| Specified Development Events
Collaborations
Contingent payments									190,100,000
Collaborative Arrangement \| Specified Product Launch Events
Collaborations
Contingent payments									$ 462,000,000.0
Strategic collaboration agreement with MDACC \| REZLIDHIA
Collaborations
Amount due to collaboration partner		$ 15,000,000.0
Collaboration period		5 years
Payment of cost share to collaboration partner											$ 5,300,000
Strategic collaboration agreement with Mdacc, clinical study enrollment support \| REZLIDHIA
Collaborations
Amount due to collaboration partner		$ 1,000,000.0
Strategic collaboration agreement with CONNECT \| REZLIDHIA
Collaborations
Amount due to collaboration partner	$ 3,000,000.0
Collaboration period	4 years